Literature DB >> 2440037

Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.

K Krohn, W G Robey, S Putney, L Arthur, P Nara, P Fischinger, R C Gallo, F Wong-Staal, A Ranki.   

Abstract

Animals immunized with native or recombinant envelope proteins from the human immunodeficiency virus (HIV, formerly referred to as human T-lymphotropic virus type III) human T-lymphotropic virus type IIIB and naturally HIV-infected men were assessed for neutralizing antibodies and cell-mediated immunity toward the virus. Immunization of rabbits or goats with the native external envelope glycoprotein gp120 or with corresponding recombinant proteins elicited strictly type-specific neutralizing antibodies. A broad, group-specific cellular immune response to gp120 and to three different HIV isolates was seen in goats immunized with the native gp120 but not in animals immunized with the nonglycosylated recombinant envelope proteins. In HIV-infected people, no T-cell response was seen, even though their T-cell response toward other foreign antigens was intact. The results show type- and group-specific epitopes on gp120, some of which may be of importance for the development of a vaccine against HIV infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440037      PMCID: PMC305233          DOI: 10.1073/pnas.84.14.4994

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Authors:  K B Cease; H Margalit; J L Cornette; S D Putney; W G Robey; C Ouyang; H Z Streicher; P J Fischinger; R C Gallo; C DeLisi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

2.  Immune functions in homosexual men with antibodies to HTLV-III in Finland.

Authors:  K Krohn; A Ranki; J Antonen; S L Valle; J Suni; A Vaheri; C Saxinger; R C Gallo
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

3.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

4.  Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I).

Authors:  H Mitsuya; H G Guo; J Cossman; M Megson; M S Reitz; S Broder
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

5.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines.

Authors:  C G Orosz; N E Zinn; R G Olsen; L E Mathes
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

7.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

8.  Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodies.

Authors:  M A Bach; F Phan-Dinh-Tuy; J F Bach; D Wallach; W E Biddison; S O Sharrow; G Goldstein; P C Kung
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus.

Authors:  P C Doherty; R M Zinkernagel
Journal:  J Exp Med       Date:  1975-02-01       Impact factor: 14.307

View more
  16 in total

1.  In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).

Authors:  R B Moss; M R Wallace; P Lanza; W Giermakowska; F C Jensen; G Theofan; C Chamberlin; S P Richieri; D J Carlo
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

2.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.

Authors:  L D Papsidero; M Sheu; F W Ruscetti
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies.

Authors:  D Dowbenko; G Nakamura; C Fennie; C Shimasaki; L Riddle; R Harris; T Gregory; L Lasky
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

4.  Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles.

Authors:  M L Michel; M Mancini; E Sobczak; V Favier; D Guetard; E M Bahraoui; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes.

Authors:  M P Nair; R Pottathil; E P Heimer; S A Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF.

Authors:  S W Pyle; G C Dubois; W G Robey; J W Bess; P J Fischinger; L O Arthur
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

Review 9.  Vaccine and antiviral strategies against infections caused by human immunodeficiency virus.

Authors:  M A Wainberg; O Kendall; N Gilmore
Journal:  CMAJ       Date:  1988-05-01       Impact factor: 8.262

10.  Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines.

Authors:  A Ranki; A Lagerstedt; V Ovod; E Aavik; K J Krohn
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.